-

GeneDx to Participate in Upcoming Investor Conferences

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in upcoming investor conferences:

  • Stifel 2025 Healthcare Conference

New York, New York

Fireside Chat: Wednesday, November 12 at 2:00 p.m. ET

  • Jefferies Global Healthcare Conference

London, UK

Presentation: Wednesday, November 19 at 11:00 a.m. GMT

  • Piper Sandler 37th Annual Healthcare Conference

New York, New York

Fireside Chat: Wednesday, December 3 at 1:30 p.m. ET

Live and archived webcasts of the presentations will be available on the “Events” section of the GeneDx investor relations website at ir.genedx.com/news-events/events.

About GeneDx
GeneDx (Nasdaq: WGS) is the global leader in rare disease diagnosis, transforming the way medicine is practiced by making genomics the starting point for health, not the last resort. We bring together unmatched clinical expertise, advanced technology, and the power of GeneDx Infinity™ – the largest rare disease dataset – built over 25 years from millions of genomic tests and deep clinical insights. This unparalleled foundation powers our ExomeDx™ and GenomeDx™ tests, giving clinicians the highest likelihood of delivering a timely, accurate diagnosis. GeneDx is shaping the future of healthcare by moving the standard of care from sick care to proactive healthcare. While our roots are in rare disease diagnosis, our commitment extends beyond – growing with the families we serve – as a trusted partner at every stage of life. For more information, visit genedx.com and connect with us on LinkedIn, Facebook, and Instagram.

Contacts

Investor Relations Contact:
Investors@GeneDx.com

Media Contact:
Press@GeneDx.com

GeneDx

NASDAQ:WGS

Release Versions

Contacts

Investor Relations Contact:
Investors@GeneDx.com

Media Contact:
Press@GeneDx.com

More News From GeneDx

GeneDx Reports First Quarter 2026 Financial Results and Updates Full-Year Outlook

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx reported first quarter financial results and business highlights, including 34% year-over-year volume growth in exome and genome testing....

GeneDx to Report First Quarter 2026 Financial Results on Monday, May 4, 2026

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS) today announced it will release financial results for the first quarter of 2026 after the market closes on Monday, May 4, 2026....

Landmark Study Shows Average Cost Savings of $80,000 Per Child and Overall Improved Health Outcomes Following GeneDx Exome and Genome Testing

GAITHERSBURG, Md.--(BUSINESS WIRE)--Landmark Study Shows Average Cost Savings of $80,000 Per Child and Overall Improved Health Outcomes Following GeneDx Exome and Genome Testing...
Back to Newsroom